Rex Fang & Innovation Equity Premium Income ETF vs Illumina, Inc. — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.47 (market cap $746.48M), while Illumina, Inc. trades at $264.95 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 53.5× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Illumina, Inc. for 83 Days on average.
| FEPI | ILMN | |
|---|---|---|
Market Cap | $746.48M | $39.95B |
Volume | 334,337 | 3,169,503 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $293.69 |
52-Week Low | $37.98 | $91.00 |
Typical Hold Time | 56 Days | 83 Days |
Enterprise Value | — | $41.31B |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →